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ABSTRACT
The pregnane X receptor (PXR) is a key regulator of
xenobiotic metabolism and disposition in liver.
However, little is known about the PXR DNA-
binding signatures in vivo, or how PXR regulates
novel direct targets on a genome-wide scale.
Therefore, we generated a roadmap of hepatic
PXR bindings in the entire mouse genome [chroma-
tin immunoprecipitation (ChIP)-Seq]. The most
frequent PXR DNA-binding motif is the AGTTCA
-like direct repeat with a 4bp spacer [direct repeat
(DR)-4)]. Surprisingly, there are also high motif
occurrences with spacers of a periodicity of 5bp,
forming a novel DR-(5n+4) pattern for PXR
binding. PXR-binding overlaps with the epigenetic
mark for gene activation (histone-H3K4-di-
methylation), but not with epigenetic marks for
gene suppression (DNA methylation or histone-
H3K27-tri-methylation) (ChIP-on-chip). After admin-
istering a PXR agonist, changes in mRNA of most
PXR-direct target genes correlate with increased
PXR binding. Specifically, increased PXR binding
triggers the trans-activation of critical drug-
metabolizing enzymes and transporters. The
mRNA induction of these genes is absent in
PXR-null mice. The current work provides the first
in vivo evidence of PXR DNA-binding signatures in
the mouse genome, paving the path for predicting
and further understanding the multifaceted roles of
PXR in liver.
INTRODUCTION
Liver is an essential ‘buffer’ for drugs and nutrient homeo-
stasis in the body. The pregnane X receptor (PXR;
NR1I2) is a key regulator in mediating xeno- and
endobiotic metabolism and disposition in liver, serving
as a critical component of the liver’s defense mechanisms
against toxic substances (1). As a member of the nuclear
receptor family, PXR is a ligand-activated transcription
factor (TF) that functions with its binding partner, the
retinoid X receptor (RXR). Once activated, the PXR/
RXR complex binds to DNA in the nucleus and regulates
gene transcription (2). PXR is highly expressed in mam-
malian liver, and its DNA-binding domain is highly
conserved across species (1). However, the ligand-binding
domain displays more variability, allowing PXR to be
activated by a wide spectrum of chemicals, including
various drugs like the antibiotic rifampicin, the
anti-inﬂammatory drug dexamethasone, and the anticon-
vulsant phenobarbital (1), environmental polybrominated
diphenyl ethers (PBDE) (3) and endogenous chemicals,
such as bile acids (4,5). Although PXR ligands can be
species speciﬁc, the target gene proﬁles share great
similarities between rodents and humans, including genes
encoding drug metabolizing enzymes and transporters
(together termed ‘drug-processing genes’ in this study).
The synthetic compound, pregnenolone-16a-carbonitrile
(PCN), is a potent activator of mouse PXR, which is
widely used by researchers to recapitulate human PXR
activation (2).
Data from this and other laboratories have shown that
numerous drug-processing genes in mouse liver are
up-regulated following PCN administration (6–10) (e.g.
our laboratory has shown that 18 drug-processing genes
are induced by PXR in mouse liver), but only a few genes
have been shown to be direct PXR targets (1,11,12). It
remains to be determined whether the induction of
critical drug-processing genes is due to direct
trans-activation by PXR or due to secondary effects.
More importantly, as it is becoming increasingly evident
that PXR has novel physiological functions, such as
trans-activating genes involved in lipid metabolism
(11,12) and cell cycle (13), novel PXR-target genes need
to be characterized, which will ﬁll a critical knowledge gap
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Numerous studies have characterized PXR response
elements, which have shown that PXR binds to AGGTC
A-like direct repeats separated by 3 or 4bp [direct repeat
(DR)-3 and DR-4] and everted repeats separated by 6 or
8bp (ER-6 and ER-8) (1). Unfortunately, most of these
ﬁndings are based on naked DNAs, or cell cultures of
non-hepatic origin with certain proteins artiﬁcially
over-expressed, or cryopreserved hepatocytes that may
have lost many features of in vivo cells. In addition,
most studies have limited the detection range for PXR
binding to the gene promoter regions. Such designs are
inherently biased, in that they do not seek to detect
novel genomic PXR-binding sites that may be equally
important for gene regulation. It is therefore necessary
to determine the most preferred DNA-binding signatures
for PXR in vivo. Recent technological advancements,
including chromatin immunoprecipitation (ChIP)-
on-chip and ChIP-sequencing (ChIP-Seq), have made
such unbiased genome-wide investigations possible
(14,15).
Next-generation sequencing technology has offered tre-
mendous opportunities for genome scale analysis of regu-
latory elements. However, the large amount of data
generated by this technology pose new challenges to in
silico tools designed for identifying the exact locations of
binding sites in DNA for TFs. For example, ChIP-Seq is
limited by the resolution of the output DNA fragments
that localize TF binding sites to  500bp. The precise
location of the binding sites within the extracted DNA
fragments needs to be identiﬁed in silico. Many different
algorithms have been proposed to address the problem of
identifying TF binding sites in promoter sequences but
with limited success (16). Traditional algorithms for
de-novo prediction of TF binding sites such as AlignAce
(5), MEME (6), MonoDi (7), etc. were not designed to
analyze large volumes of sequence data generated by
modern high-throughput technologies. As a result,
applying these algorithms to these data sets is cumber-
some, time consuming and unpractical in many situations
with solutions circumventing the problem being
sub-optimal. Therefore, for the present study, using
PXR as an example, we describe a fast, sensitive and efﬁ-
cient method for identifying the TF binding sites in large
input data sets generated from genome-scale TF binding
assays such as ChIP-chip and ChIP-Seq. The efﬁciency of
the method is derived from transforming the sequence
space to a k-mer space that has the advantage of drastic-
ally reducing the sampling space for the sampling algo-
rithm to efﬁciently operate. The k-mer transformed
sequence space makes explicit the implicit role played by
k-mers in characterizing TF binding sites. This is observed
in the fact that every TF binding site is an element of some
set of k-mers of appropriate k. The algorithm takes ad-
vantage of the fact that the total number of k-mers in a set
of input nucleotide sequences is upper bounded by the
minimum of 4
k or n   k+1, where n is the total length
of the input sequences, and, k, the length of a k-mer. For
many biological sequences, this number is far less due to
k-mer duplication. The task of identifying k-mers of
putative TF binding sites is made simpler, faster and
more efﬁcient once the k-mer distribution of the input
sequences is determined. For example, if we are interested
in ﬁnding putative TF binding sites of a length of 6 in
500 input sequences with an average length of 500bp,
instead of sampling  250000 sites in the sequence space,
one only needs to look at the frequency distribution of
4096 sites in the k-mer space. The upper bound of the
k-mer space ensures that its size does not exceed that of
the sequence space, and, due to repeated k-mers, will
almost always be much smaller than the sequence space.
The k-mer distribution of a given set of input sequences
can be determined in linear time. This enables the algo-
rithm to be repeated efﬁciently with different lengths of k,
if k is not known a priori, in order to determine the
optimum k for the TF binding sites of interest. The
motif detection algorithm that we use is a deterministic
maximally discriminative algorithm that operates on the
whole k-mer space.
A critical question arises from the common in vitro
approaches used to assess the interactions between
‘naked’ DNA and protein: how does PXR manage to
access its target genes in living cells where most DNA is
tightly packed in nucleosomes? Recently, a large body of
evidence has indicated that distinct chromatin epigenetic
signatures are essential in determining whether there is a
permissive chromatin environment for TFs to access DNA
and initiate gene transcription (17,18). DNA methylation
(DNAMe) occurs on 50-cytosine residues, which in general
prevents the recruitment of TFs to DNA, or attracts
transcription co-repressors resulting in gene silencing.
Among various types of histone modiﬁcations (acetyl-
ation, methylation, phosphorylation, ADP-ribosylation,
ubiquitination and sumoylation), a pattern has emerged
for histone H3K4 di-methylation (H3K4Me2) of ac-
tively transcribed genes, and H3K27 tri-methylation
(H3K27Me3) of silenced genes, as evident by high-
resolution proﬁling of histone methylations of the entire
human genome (18). These epigenetic signatures may be
critical in predeﬁning the transcription potential of
PXR-target genes.
Brieﬂy, the purpose of the present study is to provide
the ﬁrst in vivo knowledge of the PXR-nuclear-binding
signatures and direct-target gene proﬁles in liver both
under basal and PXR-activated conditions, to perform
an unbiased investigation of novel PXR DNA-binding
motifs and their genomic locations, to characterize
the epigenetic signatures which predeﬁne the transcription
potential of PXR-target genes, and to determine whether
critical drug-processing genes are bona ﬁde PXR targets
using PXR-null mice.
MATERIALS AND METHODS
Materials and reagents
PCN was purchased from Sigma-Aldrich (St Louis, MO).
PXR antibody (sc-25381) was from Santa Cruz (Santa
Cruz, CA). Polyclonal antibody against 5-methyl-cytosine
(ab51552) was from Abcam (Cambridge, MA). Primers
for ChIP-quantitative PCR (qPCR) were purchased
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Polyclonal antibody against methylated histone H3
proteins at lysine 4 and 27 were from Millipore Upstate
(Billerica, MA).
Animals and treatments
Wild-type (WT) C57BL/6 male mice were purchased from
Charles River Laboratories (Wilmington, MA). Breeding
pairs of PXR-null mice (2) in the C57BL/6 background
were kindly provided by Dr. Frank Gonzalez (National
Cancer Institute, Bethesda, MD). Mice were housed ac-
cording to the American Animal Association Laboratory
Animal Care guidelines, and were bred under standard
conditions at the University of Kansas Medical Center.
The animal treatments are described in detail in the
Supplementary Experimental Procedures. All animal
procedures were reviewed and approved by the
Institutional Animal Care and Use Committee at
KUMC. For ChIP-qPCR and ChIP-Seq, 8-week-old
male C57BL/6 mice were administered a single dose of
PCN (200mg/kg, i.p. in corn oil) (n=2 per time point)
or vehicle (n=1 per time point), and livers were removed
2, 8 and 12h thereafter. For mRNA assays in WT and
PXR-null mice, 8-week-old male mice (WT and PXR-null,
n=5 per group) were administered PCN or vehicle once
daily (200mg/kg, i.p. in corn oil) for 4 days, and livers
were removed on the 5th day. Livers were frozen immedi-
ately in liquid nitrogen, and stored at  80 C.
RNA isolation
Total RNA was isolated using RNA Bee reagent
(Tel-Test Inc., Friendswood, TX) as per the manufactur-
er’s protocol. RNA concentrations were quantiﬁed
using a NanoDrop Spectrophotometer (NanoDrop
Technologies, Wilmington, DE) at a wavelength of
260nm. The integrity of the total RNA samples
was evaluated by formaldehyde-agarose gel electro-
phoresis, and conﬁrmed by visualization of 18S and
28S rRNA bands.
Branched DNA Ampliﬁcation (bDNA) technology
The mRNAs of drug-processing genes Cyp3a11, Gstm3
and Oatp1a4 as direct PXR-target genes were determined
by bDNA assays (QuantiGene bDNA Signal
Ampliﬁcation Kit, Panomics, Fremont, CA). Multiple
oligonucleotide probe sets (including capture, label and
blocker probes) were designed using ProbeDesigner
Software v1.0 (Bayer Corp., Diagnostics Div.) as
described previously (19). Probe sequences for Cyp3a11,
Oatp1a4 and Gstm3 have been reported previously
(7,9,19). Equal amounts of total RNA were added to
each well of a 96-well plate. The mRNA was captured
by speciﬁc probe sets and attached to a branched DNA
ampliﬁer. Enzymatic reactions occur upon substrate
addition and the luminescence for each well is reported
as Relative Light Units (RLU).
ChIP-qPCR assay
Livers were ﬁxed with 1% formaldehyde for 15min and
quenched with 0.125M glycine. The tissues were
disaggregated with a Tissue Tearor (BioSpec Products,
Bartlesville, OK) and chromatin was isolated by adding
lysis buffer, followed by disruption with a Dounce hom-
ogenizer. Lysates were sonicated and the DNA sheared to
an average length of 300–500bp. Genomic DNA (input)
was prepared by treating aliquots of chromatin with
RNase, proteinase K and heat for de-crosslinking,
followed by ethanol precipitation. Pellets were
re-suspended and the resulting DNA was quantiﬁed with
a Nanodrop spectrophotometer. Extrapolation to the
original chromatin volume allowed quantiﬁcation of the
total chromatin yield. An aliquot of chromatin (30mg) was
precleared with protein-A agarose beads (Invitrogen,
Carlsbad, CA). Genomic DNA regions of interest were
isolated using an antibody against PXR. After incubation
at 4 C overnight, protein-A beads were used to isolate the
immune complexes. Complexes were washed, eluted from
the beads with SDS buffer, and subjected to RNase and
proteinase-K treatment. Crosslinks were reversed by incu-
bation overnight at 65 C, and ChIP DNA was puriﬁed by
phenol-chloroform extraction and ethanol precipitation.
qPCR reactions were carried out in triplicate on speciﬁc
genomic regions using SYBR Green Supermix (Bio-Rad,
Hercules, CA). The resulting signals were normalized for
primer efﬁciency by carrying out QPCR for each primer
pair using Input DNA.
ChIP-Seq analysis
Livers of control and PCN-treated mice at 8h were used
for ChIP-Seq experiments. Fragments of DNA were
tagged by 35-nt identiﬁers and subjected to sequencing
by the Illumina Genome Analyzer Sequencer based
on Solexa Technology (Illumina, San Diego, CA).
Preprocessing of the ChIP-Seq data was performed by
Genpathway (San Diego, CA). Brieﬂy, the tags identiﬁed
were mapped to the genome using Eland Software, which
resulted in a list of their chromosome coordinates. Only
tags that mapped uniquely and that have no more than
1 mismatch were retained. Because the 50-end of the
sequence tags represented the end of ChIP-fragments,
the tags were extended in silico using Genpathway
software at their 30-ends to a length of 110bp, which
was the average fragment length in the size selected
library. To identify the density of fragments (extended
tags) along the mouse genome, the genome was divided
into 32-nt bins, and the number of fragments in each bin
was determined and stored together in a BAR (Binary
Analysis Results) ﬁle. The BAR ﬁles were viewed in the
Affymetrix Integrated Genome Browser (IGB) for PXR
binding in the mouse genome. The locations of
fragment-density peaks, deﬁned by chromosome number
and a start and end coordinate, were termed as ‘intervals’.
For each BAR ﬁle, intervals were calculated using the
Affymetrix Tiling Analysis Software (TAS) and
compiled into a Browser Extensible Data (BED) ﬁle.
Three parameters of intervals were identiﬁed: threshold,
MaxGap and MinRun. Twenty-fold of input background
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tions of false discovery rate (FDR). MaxGap and
MinRun were set at 100bp. The exact locations of inter-
vals along with their proximities to gene annotations and
other genomic features were then determined. In addition,
average and peak fragment densities within intervals were
compiled. Control- and PCN-treated samples were
normalized to the sequencing depth of uniquely aligned
reads as described previously (20–24). Peaks for PXR
bindings and signiﬁcant differences between PCN and
control conditions were identiﬁed using the MACS algo-
rithm (24).
Motif analysis
In order to reﬁne the targets of PXR binding, the top
500 ChIP-DNA sequences with highest enrichment
peak values in both control and PCN-treated conditions
were retrieved from the UCSC genome browser. ChIP-
Seq data, which localizes PXR-binding regions
to  500bp, were further analyzed in silico to identify
the exact PXR-binding targets. PXR-binding proﬁles
were generated using a novel k-mer-based approach
designed for analyzing high-throughput sequence
data. The method is highly sensitive compared to other
tools for identifying putative TF binding sites (16).
As a result, it facilitates a ﬁner analysis of site proﬁles.
It is a deterministic algorithm that searches for sites
or combined half sites separated by a variable spacer
distance. The detailed description of this algorithm
is shown in a supplementary document entitled
‘motif analysis’.
Nuclear extraction from control and PCN-treated
mouse livers
Nuclear protein was extracted from liver samples using
the Nuclear Extract Kit from Active Motif (Carlsbad,
CA). Brieﬂy, livers from vehicle or PCN-treated mice
at 8h after dosing were weighed and diced into small
pieces using a clean razor blade, and collected in a
pre-chilled Dounce homogenizer. Livers were
homogenized on ice in ice-cold 1  Hypotonic Buffer sup-
plemented with DTT and Detergent (3ml of the provided
1M DTT and 3ml of the provided Detergent) (ratio: 3ml/
g tissue). The liver homogenates were incubated on ice for
15min, centrifuged for 10min at 850g at 4 C, and the
supernatant discarded. The pellet was resuspended in
1  Hypotonic Buffer and incubated for an additional
15min on ice. Detergent was added to the supernatant
(at a ratio of 1:20, detergent to supernatant) and vortexed
for 10s at the highest setting. The suspension was then
centrifuged for 30s at 14000g in a microcentrifuge
pre-cooled at 4 C. The supernatant (cytoplasmic
fraction) was discarded and the pellet (nuclear fraction
collection) was resuspended in 1  Complete Lysis
Buffer. The nuclear protein fraction was vortexed for
10s and incubated for 30min on ice on a rocking
platform. The nuclear fractions were vortexed for 10s at
the highest setting and centrifuged for 10min at
14000 g. The supernatants (nuclear protein fractions)
were transferred to new tubes and subjected to an
enzyme-linked immunosorbent assay (ELISA)-based TF
DNA-binding assay.
Oligonucleotide design for the ELISA-based TF
DNA-binding assay
Brieﬂy, for each DR-(5n+4)-like DNA sequence, two
complementary oligonucleotides were designed based on
genes that have such sequence patterns within ±10kb of
the gene loci according to the ChIP-Seq motif analysis, to
determine the biological signiﬁcance of the assay. The
forward sequence was labeled with biotin at the 30-end.
All probes have a minimum length of 50bp, with 7-bp
linker region at the 50-end, and 40-bp background se-
quences after the consensus sequence and before the
30-biotinylation. The background DNA was obtained
from sequences adjacent to the known PXR response
element DR-3 upstream of the Cyp3a11 gene locus.
Non-biotinylated oligonucleotides identical to the
biotinylated sequences, as well as non-biotinyated
mutated oligonucleotide that have two mutated nucleo-
tides in the middle of the half site (e.g. AGTTCA! AG
AACA), were designed for competition assays. DR-3-like
sequences were used as positive controls. All oligonucleo-
tides were examined by NHR-scan (25) to make sure there
are no known PXR-consensus sequences in the probe
other than the binding site of interest, and were
synthesized by Sigma Aldrich Inc. (Atlanta, GA). All the
sequences are shown in Supplementary Table S4.
ELISA-based TF DNA-binding assay
The quantiﬁcation of PXR binding to the DR-3 and DR-
(5n+4)-binding sites was determined by a modiﬁed
TransAM TF DNA-binding assay (Active Motif,
Carlsbad, CA). Because a PXR-binding kit is not commer-
cially available, the existing Active Motif TransAM Flexi
NFkB kit was modiﬁed and developed for the detection of
PXR binding to the following binding sites: DR-3
(positive control), DR-4 (when n=0), DR-9 (when
n=1), DR-14 (when n=2) and DR-19 (when n=3).
Brieﬂy, 10mg of nuclear protein extract and 1 pmol of
biotinylated oligonucleotides, corresponding to a DR-3,
DR-4, DR-9, DR-14 or DR-19 binding sites were added
to binding buffer, 1mM DTT +10ng/ml Herring sperm
DNA + Protease inhibitor cocktail (supplied as 100 
solution) in DDH2O, mixed and incubated for 30min at
room temperature (RT). Each reaction was then
transferred to an individual well of a streptavidin-coated
plate and incubated for 1h at room temperature with mild
agitation. The plate was washed three times with
phosphate-buffered saline (PBS) and primary antibody
was added (Santa Cruz sc-25381 diluted 1:1000 in 1 
TransAm Ab binding buffer for most assays, but for com-
parison of all the binding motifs (Figure 9F), the primary
antibody was diluted 1:1500 in order to better compare the
different sequences). The plate was then incubated for 1h
at room temperature without agitation. The plate was
then washed three times with PBS and secondary
antibody was added, HRP-conjugated anti-rabbit
IgG (from Active Motif) diluted 1:1000 in 1 
TransAM-binding buffer AM1. The plate was then
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The plate was washed four times with TransAM wash
buffer AM2 (from Active Motif), after which
Developing Solution (from Active Motif) was added to
each well. The plate was allowed to develop for 2–
10min after which time the reaction was stopped by
adding Stop Solution (from Active Motif). The plate
was then read at a wavelength of 450nm by a Uquant
microplate reader (BioTek, Winooski, VT). A
non-biotinylated WT oligonucleotide, identical to the
biotinylated sequence, was used to compete off PXR
binding in order to determine the speciﬁcity of each
assay (used at 10 pmol/well). A non-biotinyated mutated
(Mut) oligonucleotide was used to further conﬁrm the spe-
ciﬁcity of each assay (used at 10 pmol/well).
Microarray
Gene expression in livers of control and PCN-treated WT
mice at 12h was determined by the Affymetrix Mouse
430.20 arrays in the KUMC Microarray Core Facility.
Data were preprocessed by the Affy Expression Console
and RMA-PARTEK, and gene annotations were obtained
using GeneSpring (Agilent Technologies, CA). The detec-
tion P-value (Student’s test) was <0.05. An MA plot was
generated by R-programming and Bioconductor (26).
Brieﬂy, the probe-level microarray data (as stored in
CEL ﬁles) from control and PCN-treated groups were
pre-processed using the RMA method. The expression
values were in log2 scale. The probe intensities higher
than log2100 in either control or PCN-treatment group
were selected for graphing. An MA plot was generated
by plotting fold-changes of probe intensities (PCN/
control) against the average probe intensities between
control and PCN using the smoothScatter function in
the prada package. An interactive output of the top
5000 differentially expressed genes after PCN treatment
was generated using the annaffy package. Gene symbols
were obtained from the mouse 4302 package. All annota-
tions, including gene descriptions, chromosome IDs,
chromosome locations, GeneBank IDs, Gene IDs,
Cytoband IDs, UniGene IDs, PubMed IDs, Gene
Ontoglogies and Pathways were built in one table and
hyperlinked to on-line databases. The gene expression
data in log2 scale were constructed in the same table,
with the cells colored with varying intensities of green to
show relative expression values. The fold-changes of gene
expression (PCN/control) were listed in the last column
(descending order), with increase colored by purple, and
decrease colored by red.
Pathway analysis
Pathway analysis for control and PCN-treated microarray
data were performed using the Ingenuity Pathway
Analysis Software (IPA) (Ingenuity Systems, http://
www.ingenuity.com).
ChIP-on-chip assay of DNA methylation and histone
methylation
Genpathway’s ChIP-on-chip assays (San Diego, CA)
using Affymetrix GeneChip Mouse Tiling 2.0R E array,
were used to determine the following epigenetic proﬁles on
mouse chromosome 5, 12 and 15: DNAMe, H3K4Me2
and H3K27Me3 as described previously (27). The raw
and processed data are stored in the Gene Expression
Omnibus (GEO) database with the accession number
GSE14620.
Multiplex suspension bead array
The mRNA expression of drug metabolizing enzymes and
transporters in WT and PXR-null mouse livers were
quantiﬁed by the multiplex suspension bead array.
Brieﬂy, individual bead-based oligonucleotide probe sets
speciﬁc for each gene examined were developed by
Panomics Inc. The probe sequences are available at
http://www.panomics.com. Samples were analyzed using
a Bio-Plex 200 System Array reader with Luminex 100
X-MAP technology, and data were acquired using a
Bio-Plex Data Manager Software Version 5.0 (Bio-Rad,
Hercules, CA). Assays were performed according to the
manufacturer’s protocol. Data are expressed as the ratio
of relative light units (RLU) speciﬁc to the mRNA expres-
sion, and normalized to the internal control Gapdh. (The
raw and processed ChIP-Seq data will be stored in the
GEO database.)
RESULTS
Time-dependent mRNA induction and ChIP-qPCR of
known PXR-target genes
As a ﬁrst approach to determine whether PCN effectively
activates PXR, mRNA expression of known PXR-target
genes, namely cytochrome P450 3a11 (Cyp3a11), organic
anion transporting polypeptide 1a4 (Oatp1a4) and gluta-
thione S-transferase m3 (Gstm3) (2,7,19), was quantiﬁed
in livers of control and PCN-treated WT mice at 2, 8 and
12h after treatment (Figure 1A). Minimal to no mRNA
induction by PCN was observed 2h after treatment,
followed by a prominent mRNA induction at 8h
(Cyp3a11: 1.84-fold; Oatp1a4: 3.80-fold; Gstm3,
1.44-fold), with even more induction of Cyp3a11 and
Oatp1a4 mRNA at 12h. With this dose of PCN
(200mg/kg), mice appeared normal with no liver injury,
as evident by normal levels of serum biomarkers and
histological examinations (data not shown), suggesting
that mRNA induction was due to PXR activation rather
than pathological responses.
To determine when maximal PXR-nuclear occupancy
occurs in liver, ChIP-qPCR was performed to detect the
presence of PXR-response elements in the promoter
regions of the three PXR-target genes (Figure 1B and
C). Prior to this work, DR-3 was considered the most
preferred PXR-binding motif (28–30); therefore, DR-3s
were selected in silico using NHRscan (25) within 10kb
upstream of the transcription start sites (TSS) of the three
known PXR-target genes. Prominent PXR-binding events
were observed at  62-bp upstream of Cyp3a11 and
 5203bp upstream of Gstm3 gene loci under both
control and PCN-treated conditions. For these two
sites, both maximal PXR-binding events as well as
PXR-binding fold-change (PCN/control) were observed
Nucleic Acids Research, 2010,Vol.38, No. 22 79478h after PCN administration (Figure 1B and C).
Surprisingly, although it has been reported that Oatp1a4
is a direct PXR target in rat liver (30), none of the selected
motifs appeared to be targeted by PXR in mice. In
addition, the two distal DR-3 motifs from Cyp3a11 TSS
did not appear to be PXR targets.
In summary, PCN administration effectively trans-
activated the PXR-target genes, and although maximal
mRNA induction was observed 12h after PCN treatment,
optimal PXR-nuclear occupancy was observed 4h earlier.
Therefore, 8h was selected for subsequent PXR-binding
assays.
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Figure 1. Time-dependent mRNA induction of known PXR-target genes (Cyp3a11, Oatp1a4, and Gstm3), and ChIP-qPCR for the optimal
PXR-binding time. (A) Messenger RNA of Cyp3a11, Oatp1a4, Gstm3 in livers of control and PCN-treated WT mice at 2, 8 and 12h after treatment.
Data are expressed as relative light units (RLU) per 8mg of total RNA. (B) PXR-binding events per 1000 liver cells, normalized to untranscribed
region (background), in livers of control and PCN groups at 2, 8 and 12h after treatment. DR-3 was selected in silico as the candidate PXR-response
elements based on reports in the literature. ChIP was performed as described in ‘Materials and Methods’ section. qPCR reactions were carried out in
triplicate on selected genomic regions. Signals were normalized for primer efﬁciency by carrying out qPCR for each primer pair using input DNA.
Dashed line indicates threshold (1.5-fold of background values). Asterisks indicate regions with PXR binding at least 50% higher than background.
(C) PXR-binding ratio (PCN/control) around the target gene loci in livers of control and PCN groups at 2, 8 and 12h after treatment. Dashed line
indicates threshold (1.3-fold of control). Asterisks indicate regions with PXR-binding ratio higher than 1.3-fold.
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In order to characterize the PXR-binding signatures in the
entire mouse genome, ChIP-Seq was performed using
livers from control and PCN-treated WT mice 8h after
dosing. The sequencing reads had  11 million unique
matches from both control and PCN-treated mouse
livers, with a similar percentage of unique matches out
of the total number of tags that passed QC (control:
81%; PCN: 82%) (Table 1). After normalization, in
control mice there were 3812 active regions for positive
PXR-binding (Figure 2A), indicating a need for PXR
binding for basal functions. PCN treatment increased
the total number of active regions to 6446. This increase
in PXR binding occurred in all mouse chromosomes
(Supplementary Figure S1). Interestingly, whereas there
were 3026 common intervals between control and
PCN-treated groups, there were unique PXR-binding
sites in control only (786), and in PCN-treatment only
(3420) (Figure 2B). There were 2591 genes targeted
by PXR within ±10kb of the gene loci in control,
which increased to 3509 genes after PCN treatment
(Figure 2C). Although >70% of the PXR bindings were
located within ±10kb of the NCBI-annotated genes,
positive PXR binding was observed in the intergenic
regions ( 30%) (Figure 2D), suggesting that PXR might
have novel functions in regulating non-protein-coding
transcripts.
Using the MACS algorithm (24), we identiﬁed
1450 peaks for PXR binding that were signiﬁcantly
increased in the PCN-treated mouse liver (P=10e
 10)
(Supplementary Table S1). To determine the biological
importance of the different PXR-binding signatures in
control and PCN-treated conditions, the Ingenuity
Pathway Analysis Software (IPA) (Ingenuity

Systems,
http://www.ingenuity.com) revealed that the top
networks for genes with signiﬁcantly increased
PXR-binding peaks were mainly involved in regulation
of gene expression, drug metabolism, lipid metabolism
and metabolic diseases, indicating an adaptive mechanism
for the liver to combat chemical insult after PXR
activation.
In summary, basal PXR binding markedly increased
after ligand activation, resulting in more PXR binding
to genes involved in both xeno- and endo-biotic
metabolism.
Novel DNA-binding patterns of PXR in the mouse
genome
PXR-binding proﬁles were generated from the top 500
ChIP-DNA sequences, with highest enrichment peak
values, of both control and PCN-treated assays (control:
Supplementary Table S2 and Supplementary Figure S2;
PCN: Supplementary Table S3 and Supplementary
Figure S3). The enrichment peak values of the top 500
ChIP-DNA sequences varied between 1575 and 47
(mean 94, and SD 134.8) in the control group, and 2099
and 79 (mean 154 and SD 170.5) in the PCN-treated
group. The overlap between the two groups was quantiﬁed
in terms of the number of common 150-mers (150bp was
the length of the analyzed sequence segments, set as a
parameter, k0, in the motif detection algorithm described
in methods) between them. Of the 171324 unique
150-mers in the control group and 225746 unique
150-mers in the PCN-treated group, only 2287 were
common to both groups, suggesting a signiﬁcant differ-
ence between the sequences of the two groups. The
reason for the difference can be attributed to the marked
increase in the number of bound sequences, and the
increased binding intensity of PXR after PCN treatment.
The current work offers new insights into the binding
patterns of PXR, suggesting a distinct correlation in the
spacer distance between the two nuclear receptor half sites
of high-afﬁnity binding sites that span a distance much
further than the furthest spacer (8bp) reported in the lit-
erature. Whereas the direct repeats, DR-3 and DR-4, of
the well-established consensus motif AGTTCA featured
prominently in our analysis, the everted repeats, ER-6
and ER-8, cited in the literature as PXR-binding motifs
(1), was less evident (Figure 8). The current analysis
suggests that by far the most favored spacer conﬁguration
for PXR binding in both control and PCN-treated mouse
livers is DR-4 (Figure 3A–C: PCN treatment;
Supplementary Figure S2 top motif A–C: control).
Interestingly, the spacer distance distribution of half
sites of the consensus direct repeat AGTTCA shows
clear peaks at isochronal intervals of 5bp, corresponding
to spacer distances of 4, 9, 14, 19 and so on (i.e. spacer
distances of the form 5n+4, n=0 ,1 ,2 , ...), extending to
over a hundred base pairs (spacer distance distribution,
Table 1. General sequencing information for the PXR ChIP-Seq
experiments in mouse livers
Sequencing information Control PCN
Total tags (lines in export ﬁle) 21993489 21051280
Unique match 14389148 13985170
No match 5616115 5167805
QC (excess Ns) 208511 194388
non-unique match 1729781 1671711
musribosomal 17244 15876
newcontam.fa 32690 16330
Total tags passed quality control ﬁltering 14248265 13097656
Unique match 11510955 10803383
% Unique match/total tags passed 81% 82%
No match 1262350 931692
QC (excess Ns) 14838 10756
non-unique match 1419985 1326822
musribosomal 14059 12574
newcontam.fa 26078 12429
Total tags failed quality control ﬁltering 7745224 7953624
Unique match 2878193 3181787
No match 4353765 4236113
QC (excess Ns) 193673 183632
non-unique match 309796 344889
musribosomal 3185 3302
newcontam.fa 6612 3901
ChIP-Seq was performed using livers from control and PCN-treated
wild-typeWT mice as described in ‘Materials and Methods’ section.
Total tags and the total tags that passed quality control ﬁltering
([including unique match, no match, QC [(excess Ns]), non-unique
match, musribosomal, and newcontam.fa), as well as percentage of
unique match/total tags that passed quanlity control ﬁltering, are
listed in this table.
Nucleic Acids Research, 2010,Vol.38, No. 22 7949Figure 3C: PCN treatment; Supplementary Figure S2 top
motif C: control). This reveals a new structural conﬁgur-
ation of half sites that favors a spacer distance that is
periodically correlated with a period of 5bp (sample
partial correlations, Figure 3D: PCN treatment;
Supplementary Figure S2 top motif D: control). It also
indicates that the binding of PXR to the consensus
direct repeat AGTTCA is partial to response elements
with a spacer distance of 5n+4 between half sites over
the proximity of the half sites to each other. The
observed tapering of peak densities of these sites can be,
as expected, explained by the increasing motif length [a
regression ﬁt on spacer distance explains 80% of the vari-
ation between peak densities (Figure 3C: regression line)];
however, the signiﬁcantly high density of DR-4 suggests
that proximity between half sites is desired by PXR on a
secondary level.
To conﬁrm that DR-(5n+4) is indeed the most
preferred PXR-binding motifs, we analyzed the distribu-
tion of binding afﬁnities of sequences with response
elements of the form DR-(5n+0), (5n+1), (5n+2),
(5n+3) and (5n+4) by comparing their mean sequence
ranks, ranked on binding afﬁnity. The enrichment peak
values from ChIP-Seq data were used as a surrogate
for binding afﬁnity. Ranks were assigned in descending
order of binding afﬁnity, such that sequences with high
afﬁnity received a low rank. This analysis did indeed
reveal a strong association between sequences with
DR-(5n+4) response elements and high-binding afﬁnity
(multiple comparison, Figure 3E: PCN treatment;
Supplementary Figure S2 top motif E: control).
Figure 3E shows a multiple comparison plot of the
mean sequence ranks with comparison intervals around
them. Means in Figure 3E with comparison intervals
that do not overlap are different at a signiﬁcance level of
 <0.02. Furthermore, the results of a pair-wise compari-
son of the mean sequence rank between sequences with the
different forms of response elements is shown in
Supplementary Table S5, after a Bonferroni multiple test
correction at a 98% conﬁdence level. It is evident from
Figure 3E and Supplementary Table S5 that DR-(5n+4),
with the lowest rank, is the most common PXR-binding
conﬁguration. Similar results to the above were obtained
when the multiple comparison tests were carried out
directly on peak value instead of sequence rank (data
not shown). Sequences with DR-(5n+3) response
elements had the second highest binding afﬁnity, of
which DR-3 is the ﬁrst element. However, there is no
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7950 Nucleic Acids Research, 2010,Vol.38, No. 22Figure 3. PXR DNA-binding proﬁles of the highest scoring motif (MAP score 6345.15, number of hits=4744, number of seq. hit=370) obtained
from in silico analysis of ChIP-Seq data of PXR binding after PCN treatment. (A) Sequence logo representing the sequence conservation of the 30
half site. (B) Sequence logo representing the sequence conservation of the 50 half site. (C) Spacer distance distribution between the two half sites.
Diamonds mark densities at spacer distances of 5n+4. The linear regression line ( 0= 0.83,  1=120.75, norm of residuals=70.14) of these points
is shown with 95% conﬁdence bounds (dash lines). (D) Sample partial autocorrelation function of the spacer distance distribution in (C), with 95%
conﬁdence bounds. The lag corresponds to distance in base pairs. A signiﬁcantly high lag of 5bp in the PACF suggests the presence of a recurring
pattern of high site density occurring at 5-bp intervals. (E) Multiple comparison plot of mean sequence rank on binding afﬁnity of the AGTTCA-like
direct repeat with spacer distances of the form 5n+0, 5n+1, 5n+2, 5n+3 and 5n+4, with comparison intervals around the mean estimates. Means
with comparison intervals that do not overlap are signiﬁcantly different at a signiﬁcance level of  <0.02. (F) Illustration of the accordion model to
explain the binding density of the PXR homodimer to AGTTCA like direct repeats with a 5n+4bp spacer distance. The PXR homodimer interface
has a 10 b-strand structure that stretches to accommodate the spacer distances between the two DNA binding domains of the PXR/RXR complex as
n increases.
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response elements with other spacer distances. The distri-
bution of binding afﬁnities did not vary signiﬁcantly
between the sequences with DR-(5n+4) response
elements (a t-test comparison between the top and
bottom 50th percentile of sequences with DR-(5n+4)
response elements reveled no signiﬁcant difference in
their mean sequence ranks, P=0.59). As can be seen,
these results are observed in both PXR binding under
PCN-treated and control conditions, however, as
expected the observed patterns are much stronger in the
PCN-treated assay than control.
As a negative control, we analyzed the background se-
quences of the same ChIP-Seq data for characteristics of
the observed high-afﬁnity response elements for both
control and PCN-treated assays. The background se-
quences were comprised of all non-overlapping 500-bp
upstream and 500-bp downstream sequence segments of
the top 500 ChIP-DNA sequences. As expected, the
relative abundance of high-afﬁnity binding sites was sub-
stantially low in the background sequences. For example,
the hit ratio (i.e. the ratio of the number of observed sites
to the total number of possible sites) of the consensus
direct repeat AGTTCA in the background sequences of
the control and PCN-treated assays was 0.91 and 0.89%,
respectively, compared to 3.70 and 4.83% in the ChIP
DNA sequences. Less than 50% of the background se-
quences contained the consensus direct repeat AGTTCA
as opposed to 74% of the PCN-treated ChIP DNA se-
quences and 52% of the control ChIP DNA sequences.
Furthermore, unlike the ChIP DNA sequences, the back-
ground sequences displayed a uniform spacer distance
distribution between half sites devoid of any periodic
relationship in both control and PCN-treated groups
(Supplementary Figure S4: control; Supplementary
Figure S5: PCN treatment). This further corroborates
the signiﬁcance of the (5n+4)-bp spacer distance conﬁg-
uration between half sites in the binding of PXR to DNA.
In order to ensure that no one sequence disproportionate-
ly inﬂuenced the observed PXR-binding patterns, we ﬁrst
augmented the total number of sequences by 10 to include
the top 510 ChIP DNA sequences, and then randomly
selected 500 of those sequences for a similar analysis.
The procedure was repeated 100 times. The results from
these experiments were consistent with our initial obser-
vations for ChIP DNA sequences from both PCN-treated
and control groups (data not shown).
In summary, genome-wide motif analysis has revealed a
novel structural conﬁguration of DR-(5n+4) as the major
PXR-binding signature in the mouse genome, with the
strongest preference towards DR-4. An ‘accordion
model’ (Figure 3F), described in the ‘Discussion’ section,
has been proposed to explain this observation.
ELISA-based TF binding assay conﬁrmed novel
DR-(5n+4)-like sequences are functional
PXR-binding sites
In order to quantify binding of PXR to the different
DNA-binding motifs, we developed a quantitative
ELISA-based TF DNA-binding assay. The assay was
developed from an existing commercially available kit
for the detection of other TFs (Active Motif, Carlsbad,
CA), and modiﬁed accordingly for the detection of
PXR. A detailed description of the modiﬁcations to the
assay can be found in the ‘Materials and methods’ section.
As shown in Figure 9, this assay can detect basal binding
(CON) and PCN-induced binding (PCN) of PXR to the
following binding sites: DR-3, DR-4, DR-9, DR-14 and
DR-19. For each binding site, nuclear protein from
PCN-treated mouse liver resulted in increased PXR
binding to the DNA sequence. In addition, binding of
PXR to each DNA-binding site was effectively competed
off with an unlabeled competitor oligonucleotide, whereas
mutated unlabeled oligonucleotides were either ineffective
or much less effective in competing with the labeled DNA
sequences. Interestingly, under these binding conditions,
PXR binding was strongest to DR-19, followed by DR-14,
whereas DR-9, DR-4 and DR-3 were relatively compar-
able (Figure 9F). Collectively, these data demonstrate that
PXR binds to the DR-(5n+4)-binding motif in
PCN-treated mouse liver.
To further justify the functional signiﬁcance of DR-
(5n+4)s in gene regulation, we performed a global
analysis of the genes that carry DR-(5n+4)-like sequences
within the PXR-ChIP DNA fragments. For these genes,
we compared the fold changes of PXR bindings and
mRNA differential expression after PCN treatment.
Among all the PXR-direct target genes that carry DR-
(5n+4),  36% of genes fall into the top 5000 differentially
regulated genes (Supplementary Table S6) after PCN
treatment. Among these differentially regulated genes,
the majority of the altered mRNA expression (both induc-
tion and suppression) corresponds to increased
PXR-binding to the DR-(5n+4) (60% for induced
genes, and 75% for suppressed genes), suggesting that
DR-(5n+4) indeed has functional signiﬁcance in
PXR-mediated gene regulation.
Microarray analysis reveals both PCN-induced and
suppressed gene batteries correlate with increased
PXR binding
To determine whether alterations in PXR binding have
biological effects on gene regulation, mRNA microarray
experiments were performed in control and PCN-treated
WT mice 12h after administration. PCN-treatment
revealed both induced (Figure 4A, above red line) and
suppressed (Figure 4A, below blue line) gene batteries.
Approximately 7.4% of mouse liver genes were induced
and 4.5% suppressed by PCN treatment (Figure 4B).
Because PXR is a well-known transcription activator for
numerous drug-processing genes, we hypothesized that
more PXR binding after PCN treatment would result in
mRNA induction. To test this hypothesis, an overlay
was performed between microarray and ChIP-seq data
(Figure 4C and D). For the direct PXR targets, there
were 401 genes in the induction battery by PCN
(26.1%), and the majority of these genes had increased
PXR binding (18.0%) (Figure 4C). For the
PCN-suppressed gene battery, 300 genes (32.1%) were
direct PXR targets, and surprisingly, the majority of
7952 Nucleic Acids Research, 2010,Vol.38, No. 22these down-regulated genes (17.3%) also had increased
PXR binding, indicating that PXR might have both in-
duction and suppression functions in gene regulation
(Figure 4D). Ingenuity Pathway Analysis demonstrated
that induced direct PXR-target gene batteries were
mainly involved in adaptive responses like cell prolifer-
ation, cell signaling, and drug metabolism. In contrast,
the suppressed direct PXR-target gene batteries were
mainly involved in basal maintenance functions like
amino acid and carbohydrate metabolism
(Supplementary Table S7). Fold changes of gene expres-
sion corresponding to alterations in PXR binding are
listed in Supplementary Tables S8 (induced gene battery)
and S9 (suppressed gene battery). An interactive output of
the top 5000 differentially regulated genes by PCN linked
to their online databases (probe ID, symbol, description,
chromosome location, GeneBank ID, PubMed ID, Gene
Ontology, Pathways, etc.) was constructed and available
in Supplementary Table S10. Approximately 70% of the
genes in both PCN induced and suppressed gene batteries
were indirect PXR targets, likely due to a ‘butterﬂy effect’
triggered by PXR binding to genes encoding upstream
regulatory factors, or due to the off-target effects of
PCN. In summary, PXR appears to have dual functions
in gene regulation. The majority of both induction and
suppression of direct PXR-target genes appear to be due
to increased PXR binding. Whereas the suppressed PXR
direct target gene battery was mainly involved in nutrient
homeostasis and cell maintenance, the induced gene
battery was important for drug metabolism and cell
proliferation.
Co-existence of distinct epigenetic signatures favors PXR
binding to DNA
The PXR-nuclear-binding signatures have raised the
question of whether a permissive chromatin environment
pre-exists at PXR-binding sites favoring the interaction
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Nucleic Acids Research, 2010,Vol.38, No. 22 7953between PXR protein and DNA. To explore the
pre-existence of chromatin epigenetic signatures in
predeﬁning the binding signatures of PXR, three epigen-
etic marks, namely DNAMe, H3K4Me2 and H3K27Me3,
were examined by ChIP-on-chip.
Because PXR is a key regulator of drug metabolism and
transport in liver, the present study ﬁrst aims to under-
stand how epigenetic marks regulate the recruitment of
PXR to its prototypical target genes encoding drug
metabolizing enzymes and transporters. Therefore, as a
ﬁrst attempt to discover the roles of epigenetic signatures
in regulating PXR binding to drug-processing genes, we
selected chromosomes 5, 12 and 15, because these chromo-
somes are enriched with drug-processing genes (e.g. these
chromosomes contain all the Cyp3a gene subfamily, Ugt2
and Ugt3 gene clusters, and the Mdr gene cluster). An
overlay was performed between these epigenetic signatures
and PXR binding (ChIP-Seq) in both control and
PCN-treated conditions. As expected, there were more
nucleotides covered by PXR after PCN treatment
(Figure 5A). Minimal overlapping was observed between
PXR binding and the non-permissive epigenetic mark
DNAMe in control mice (0, 491 and 62bp on chr 5, 12
and 15, respectively), and even less in PCN-treated mice
(0, 337 and 30bp on chr 5, 12 and chr15, respectively)
(Figure 5B). In contrast, prominent portions of
PXR-bound nucleotides overlapped with the permissive
mark H3K4Me2 in control (824, 596 and 1130bp on chr
5, 12 and 15, respectively), and even more after PCN treat-
ment (1379, 607 and 1964bp on chr 5, 12 and 15, respect-
ively) (Figure 5C). There was no overlapping between
PXR binding and the non-permissive mark H3K27Me3
in either control or PCN-treated conditions (0bp
overlap) (Figure 5D). The total number of nucleotides
covered by each epigenetic mark, as well as other
overlapping information among the three epigenetic
marks and PXR binding (control and PCN) are shown
in Supplementary Table S11 (A: numbers of overlapping
nucleotides; B: percentage of overlapping nucleotides).
Speciﬁcally, on chromosome 5, as we reported pre-
viously (31), the prototypical PXR-target gene Cyp3a11
is marked with strong enrichment of H3K4Me2, without
any enrichment of DNAMe or H3K27Me3.
Corresponding to such a permissive chromatin environ-
ment, there is enriched PXR binding in control mice
with two positive binding sites, with even more PXR
bindings after PCN-treatment (11 positive binding sites,
highest peak value: 108-fold) (Figure 6A), and the
Cyp3a11 mRNA was up-regulated by PCN in a
PXR-dependent manner (Figure 1A and Table 2).
In addition, we analyzed the chromatin epigenetic sig-
natures, the PXR-binding signatures, and target gene ex-
pression of a few other known PXR direct target genes
deﬁned by in vitro assays, including CD36, which encodes
a fatty acid transporter for lipid homeostasis (12), as well
as Mdr1a and Mdr1b, which encode the P-glycoprotein
transporters for drug-excretion (29,32). Interestingly,
there was no enrichment of H3K4Me2 around the CD36
gene locus (data not shown), and corresponding to the
absence of the H3K4Me2, there was no PXR bindings
observed within ±10kb of the entire CD36 gene locus
(Supplementary Figure S6A), indicating that
PXR-binding sites are likely masked in chromatin when
a permissive epigenetic mark is absent. In addition, the
CD36 mRNA was not induced after PCN-treatment
in vivo (data not shown). For the Mdr1s, there was a
strong enrichment in the non-permissive mark DNAMe
in the 30-UTR of both Mdr1a and 1b (Mdr1a, 5.47-fold;
Mdr1b: 5.06-fold; threshold: 3.0-fold of input background
signal) (Supplementary Figure S6B), and corresponding to
such a non-permissive chromatin environment marked by
DNAMe, there were no observed PXR bindings in control
mouse liver, and after PCN-treatment, only one site with
very low enrichment of PXR bindings was observed in
Mdr1a (40-fold) and Mdr1b (31-fold) gene loci
(Supplementary Figure S6C). As we previously reported
(33), Mdr1a and 1b mRNAs are low in liver under basal
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7954 Nucleic Acids Research, 2010,Vol.38, No. 22conditions, and neither was inducible by PXR ligands.
These data serve as a negative control that further corrob-
orates the importance of a pre-existing chromatin epigen-
etic environment in deﬁning the transcription potential of
PXR-target genes. The known PXR-direct targets, evident
by in vitro assays in the literature, are not necessarily
targeted by PXR in vivo, unless a permissive epigenetic
signal pre-exists around the chromatin.
Taken together, these observations indicate the import-
ance of a permissive chromatin environment for PXR
binding and trans-activation of target genes. Genomic
regions marked with non-permissive epigenetic signatures,
namely DNAMe and H3K27Me3, did not appear to
interact with PXR protein. Conversely, the presence of
the permissive epigenetic mark H3K4Me2 appears to at
least partially contribute in recruiting PXR to target DNA
sequences.
ChIP-Seq reveals novel PXR-binding sites within critical
drug-processing gene loci
Most PXR-binding studies in the literature have only
examined the promoter regions of a few genes. To deter-
mine whether novel PXR-binding sites exist in other
regions of a particular gene, PXR binding within
±10kb of an entire gene locus was examined in the
Integrated Genome Browser (IGB). Because PXR is a
critical xenobiotic sensor, we focused on genes encoding
Phase I and II drug-metabolizing enzymes and transport-
ers. Cyp3a11 has two positive PXR-binding sites in
controls ( 58 and  1578bp from the TSS), with peak
values 36- and 46-fold higher than background signals,
respectively (threshold: average peak value >20-fold)
(Figure 6A). After PCN treatment, PXR bindings at
 1594bp further increased to 94-fold above background,
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Figure 6. Location and fold enrichment of PXR binding to the representative drug-processing gene loci in control and PCN-treated groups. Image
was generated by Integrated Genome Browser. (A) Cyp3a11; (B) Gstm2 and 3; (C) Abcc3 (Mrp3).
Nucleic Acids Research, 2010,Vol.38, No. 22 7955and in addition, 10 new binding sites emerged, 9 of which
were intronic (108-fold at 374-bp downstream of
TSS, 40-fold at 1622bp, 29-fold at 5558bp, 34-fold at
6246bp, 35-fold at 8326bp, 27-fold at 9750bp, 29-fold
at 16198bp, 33-fold at 16519bp, 31-fold at 17270bp
downstream of TSS), and one downstream of the gene
locus (31-fold at 25398-bp downstream of TSS).
Similarly, Cyp2b10, which encodes another cytochrome
P450 enzyme for Phase I metabolism, showed both
enhanced PXR-binding intensity (64- to 255-fold at
 2299bp, and 44- to 174-fold at  4267bp) and
an increase in the number of binding sites (two sites
in control, three sites after PCN treatment; new site:
235-fold at  9611bp) after PCN treatment, but all
the binding locations were restricted to the upstream
region from the TSS (Supplementary Figure S7A).
Aldh1a1, which encodes a critical aldehyde dehydrogenase
for the oxidation of aldehyde products from lipid
peroxidation, had only one PXR-binding site localized
to an intron region (38-fold at 29256-bp downstream of
TSS), with further enrichment in PXR binding at approxi-
mately the same site after PCN administration (63-fold at
29240-bp downstream of TSS) (Supplementary
Figure S7B).
For Phase II metabolism, a few Gst genes, which encode
glutathione S-transferases, essential for detoxifying
electrophiles and free radicals, were selected. Gstm2
and Gstm3 form a polycistron cluster on the chromosome
(Figure 6B). In control conditions, there were three
PXR-binding sites observed in this cluster. After PCN
treatment, there was a marked increase in PXR binding
in all three sites, and in addition, two new PXR-binding
sites emerged within the cluster. In contrast, Gstm1
had only one PXR-binding site that was located
upstream of the TSS (42-fold at  7525bp), with higher
binding intensity after PCN-treatment (104-fold at
 7573bp). Gsta1 had two PXR-binding sites upstream
of the TSS in control ( 797 and  7277bp), and it
gained one more binding site located inside the gene
after PCN treatment (75-fold at 1538-bp downstream of
TSS), in addition to increased binding intensities at the
other two positions (Supplementary Figure S8A and B).
The 30-phosphoadenosine 50-phosphosulfate synthase
2 (Papss2), a protein which synthesizes the active
sulfate (PAPS) for the sulfation of chemicals, had
PXR bindings exclusively within the Papss2 gene in
control (62-fold at 2305bp, 210-fold at 6913bp, 30-fold
at 7249bp, 37-fold at 8241bp and 80-fold at 17521bp
downstream of TSS), and both the binding intensity and
number of binding sites increased after PCN-treatment
(112-fold at 2321bp, 364-fold at 7089bp, 133-fold at
17537bp, 57-fold at 31233bp and 30-fold at 33137bp)
(Supplementary Figure S8C).
For transporters, the uptake transporter Slco1a4
(Oatp1a4) and the efﬂux transporter Abcc3 (multidrug
resistance related protein 3, Mrp3) are important for
moving drugs in and out of hepatocytes. A strong enrich-
ment in PXR binding was observed as far as 10-kb
upstream from the Oatp1a4 TSS (277-fold), which was
further enriched at this position after PCN treatment
(549-fold) (Supplementary Figure S9). There were no
PXR-binding sites within the gene or further downstream.
In contrast, Mrp3 had three positive PXR-binding sites
only inside the gene (45538, 30722 and 3810bp down-
stream of TSS), with further enriched PXR binding at
approximately the same regions after PCN treatment
Table 2. PXR-DNA-binding enrichments and mRNA expression of selected drug-processing genes in mouse liver in control and PCN-treated
conditions
Genes PXR binding
average peak
PXR binding
average peak
PXR binding
fold change
mRNA
fold change
mRNA
fold change
Phase I WT-Corn Oil WT-PCN WT PCN/Corn Oil WT PCN/Corn Oil PXR-null PCN/Corn Oil
Cyp3a11 14.73 44.64
a 3.03 (increase) 1.74
b 1.072
Cyp2b10 47.33
a 221.33
a 4.68 (increase) 3.63
b 1.30
Aldh1a1 38.00
a 63.00
a 1.66 (increase) 1.26
b 0.98
Aldh3a2 NA NA NA 0.89 1.07
Aldh6a1 NA NA NA 0.89 1.06
Aldh7a1 NA NA NA 0.98 1.14
Phase II WT-Corn Oil WT-PCN PXR binding fold change WT PCN/Corn Oil PXR-null PCN/Corn Oil
Gsta1 40.00
a 66.00
a 1.65 (increase) 15.65
b 0.79
Gstm1 42.00
a 104.00
a 2.48 (increase) 1.99
b 1.08
Gstm2 44.60
a 179.60
a 4.03 (increase) 1.98
b 0.85
Gstm3 49.50
a 215.00
a 4.34 (increase) 16.02
b 0.81
Gstm4 NA NA NA 1.25 1.00
Gstm5 NA NA NA 0.82 1.00
PAPss2 69.50
a 119.00
a 1.71 (increase) 1.29
b 1.03
Transporters WT-corn oil WT-PCN PCN/corn oil WT-PCN/corn oil PXR-null PCN/corn oil
Oatp1a4 277.00
a 549.00
a 1.98 (increase) 4.24
b 1.05
Mrp3 73.33
a 120.33
a 1.64 (increase) 2.52
b 1.05
Mrp5 NA NA NA 0.63 0.91
The average peaks for PXR–DNA binding, fold-changes of PXR–DNA binding, as well as the mRNA fold-changes in WT and PXR-null mouse
livers are shown in the table. The drug-processing genes are classiﬁed into three groups: phase-I, phase-II, and transporters.
NA: no PXR binding.
aPXR binding above threshold (20).
bStatistically signiﬁcant.
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(Figure 6C).
In summary, contrary to the biased detection of PXR
binding in the literature, which restricted the detection
only to upstream promoter regions, ChIP-seq re-
vealed novel PXR-binding sites in drug-processing gene
loci, highlighting several interesting patterns: (i) PXR
proteins can bind to upstream, downstream, or the
intronic regions of a gene locus, (ii) polycistron clusters
of genes can share the same PXR-binding sites
and (iii) after administering the PXR-ligand, the target
genes either gain more PXR-binding sites, and/or
more enriched binding intensity at the original binding
position.
To determine the global signiﬁcance of PXR bindings
in gene regulation, all the PXR DNA-binding intervals
that are speciﬁcally located upstream, downstream
and within a particular gene were selected as shown
in Supplementary Table S12, and the mRNA expression
of the genes with PXR bindings in these regions
was examined and shown in Supplementary Table S13.
Overall, there are 1346 intervals located speciﬁcally
to the upstream of the TSS of genes, 550 in control, and
796 in PCN-treated group; 664 intervals downstream
(242 in control and 422 in PCN-treated group); 3871 inter-
vals located in genes (1389 in control and 2482 in
PCN-treated group) (Supplementary Table S12). A conﬁ-
dence score (P-value) was calculated between altered
PXR binding and changes in gene expression.
Interestingly, although the P-values for the upstream
and downstream genes are not signiﬁcant, it is signiﬁcant
for PXR binding within the genes, highlighting the im-
portance of intronic PXR bindings in regulating target
gene expression.
To strengthen the evidence that critical drug-
processing genes in liver are bona ﬁde PXR targets, we
performed mRNA assays of these genes in control
and PCN-treated WT and PXR-null mice (Table 2). The
Phase I metabolism genes, Cyp3a11, Cyp2b10 and
Aldh1a1, all had increased PXR binding after PCN
treatment, corresponding to a signiﬁcant increase in
mRNA expression of these genes in livers of WT mice.
Such mRNA induction was not observed in PXR-null
mice (Table 2). As a negative control, Aldh3a2, 6a1 and
7a1, which have no PXR binding regardless of PCN treat-
ment, were selected. As expected, the mRNAs of these
genes were not altered by PCN in either WT or
PXR-null mice.
In Phase II metabolism, the mRNAs of Gsta1, m1, m2,
m3, as well as Papss2 were induced by PCN in WT mice
corresponding to more PXR binding. Such mRNA induc-
tion was blocked in PXR-null mice. For Gstm4 and m5,
PXR did not bind in either control mice or PCN-treated
mice, and there was no change in mRNA expression in
livers of either WT or PXR-null mice.
Similarly, the mRNAs of the transporters, Oatp1a4 and
Mrp3 were induced by PCN in WT mice, corresponding to
increased PXR binding, but no mRNA induction was
observed in PXR-null mice. As a negative control,
Mrp5, which had no PXR binding regardless of
PCN-treatment, had no changes in mRNA expression in
either WT or PXR-null mice.
DR-4 is the motif of choice for PXR-targeted
drug-processing genes
For all these drug-processing genes directly targeted by
PXR, local motif analysis of their ChIP DNA fragments
further justiﬁed DR-4 as the most prevalent DNA-binding
motif for PXR after PCN treatment (Figure 7), suggesting
that trans-activation of these critical drug-processing
genes is mainly due to a DR-4 effect.
Taken together, the present data have established
positive associations between PXR-binding and mRNA
induction of critical drug-processing genes, and using
PXR-null mice, we have conﬁrmed that PXR is necessary
in trans-activating these genes.
DISCUSSION
The present study has provided the ﬁrst in vivo evidence of
PXR-nuclear binding signatures in mouse liver on a
genome-wide scale, both under basal conditions and
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Figure 7. The densities of the PXR DNA-binding motifs (DR-0 to
DR-4) among all the PXR-bound drug-processing genes in control
(A) and PCN-treated mouse livers (B).
Nucleic Acids Research, 2010,Vol.38, No. 22 7957after chemical activation. Unbiased ChIP-Seq has
demonstrated that DR-4 is the most preferred
DNA-binding motif of the PXR protein, challenging the
existing paradigm that implies DR-3 and ER-6 as the
common PXR-binding motifs. Furthermore, in silico
motif analysis has shed light to a novel DNA-binding
pattern for PXR binding, with a strict spacer requirement
of 5n + 4 nucleotides between the two direct-repeat half
sites. PXR appears to have dual functions in gene regula-
tion, as the majority of both induced and suppressed
PXR-direct target genes correspond to more PXR
binding. In addition, using ChIP-on-chip, we have
investigated the importance of three distinct epigenetic
signatures in predeﬁning the PXR-binding patterns and
transcription potential. Finally, we have characterized
novel PXR-binding locations within the drug-processing
gene loci, and used PXR-null mice to justify that these
drug-processing genes are bona ﬁde PXR targets.
The arrival of a new generation of high-throughput
technologies for querying TF binding sites in their native
environment in a whole genome scale has brought about a
new set of challenges to computational tools that perform
ab initio prediction of DNA-binding targets. Foremost
among them is the need to deal with very large datasets.
Large datasets create a strain on traditional algorithms
designed for this task; as a result, many of them place
strict limitations on the size of their input datasets. We
addressed this problem by transforming the sequence
space, on which traditional algorithms operate, to a k-
mer space. The transformation from sequence space to
k-mer space can be achieved in linear time for all reason-
able length TF binding sites. Working in the k-mer space
is efﬁcient, not only due to its substantially smaller size,
but also because of its indexing properties that provide
rapid access to individual k-mers. This not only paves
the way for analyzing large data sets but also facilitates
the analysis of a wider contrast of the target binding sites.
This is very advantageous when working with response
elements that are nuclear receptor half sites with
variable spacer distances. A testament to this is the com-
prehensive analysis of PXR-binding targets in the mouse
genome described in this article.
More interestingly, we have established a new binding
paradigm that emphasizes on a isochronously extending
spacer distance between half sites. The PXR protein shows
a clear binding preference to the AGTTCA consensus
direct repeat with a spacer distance of (5n+4) bps
between the two half sites, suggesting that PXR binding
depends more on a distinct periodically related conﬁgur-
ation, rather than the simple proximity between the two
half sites. There is no observable difference in binding
afﬁnity of response elements with half sites on the same
face (half sites with spacer distances of the form, 10n+4),
or on opposite faces (half sites with spacer distances of the
form, 10n+9), (t-test, P=0.76). This novel and interest-
ing observation raises the question of whether there are
any intrinsic features in the DNA or the PXR–protein
complex enforcing such a periodic pattern. As
demonstrated by Watson and Crick in 1953, the double
helical structure of DNA has a 3.4A ˚ interval between
the two adjacent bases, with 10 such intervals per turn
(34A ˚ ) (34). If one assumes that at the very beginning of
PXR binding, the double helical structure of DNA is still
preserved with only partial destruction of hydrogen
bonds, then the length of one AGTTCA-like half site
exactly matches the length of half a helical turn from
trough to peak [3.4A ˚  (6–1)=17A ˚ ]. Therefore, DR-4,
which is most preferred by the PXR–protein complex
(Figure 3C, Supplementary Figure S2 top motif C and
S3 top motif C), will form a structure of three half turns
in tandem, with the 4bp spacers occupying the middle half
turn (Figure 3F). Similarly, DR-9 incorporates one more
half turn between the two half sites, as ﬁve new intervals
are introduced in the spacer region (Figure 3F). Following
this rule, as n half turns are incorporated between the two
half sites, a DR (5n+4) pattern emerges (n=0,1,2,...),
which has a tandem structure of two half sites on the
outermost half turns, and (n+1) half turns in between,
forming the spacer region. Based on the observations in
the present study (Figure 3C), it seems that DNA interacts
with PXR protein in a functional unit of half a helical
turn, which means DNA is more likely targeted by PXR
if there are two AGTTCA-like half sites still preserved in
the helical structure, separated by at least one half turn in
between.
If the proposed structure of DR (5n+4) is really the
preferred DNA conﬁguration for PXR binding, it
suggests that some symmetry exists in the PXR–protein
complex. Based on amino acid sequence alignment, we
predicted the 3D structure of the mouse PXR protein.
The mouse PXR ligand binding domain shows highest
similarity to the tethered human PXR-LBDSRC-1p apo-
protein (35) (PDB ID: 3CTB; E value: 8e 139), which
forms a PXR–PXR homodimer interfaced with 10-b
strands. Very recently, computational biologists have
demonstrated that PXR functions as a heterotetramer
with the unique b-stranded interface of the PXR
homodimer in the middle, and two RXR proteins on the
outside (36). In addition, the key amino acids forming the
homodimer interface are highly conserved across species
and the disruption of these amino acids result in decreased
transcription activity of PXR (37).
Based on the above evidence, we propose an ‘accordion
model’ to explain the interesting phenomenon of the DR-
(5n+4) periodic PXR-DNA binding patterns (Figure 3F).
The basic assumption of this model is that the PXR
homodimer interface, which has a b-sheet structure with
10 b-strands, is stretchable like the bellows of an accor-
dion that ﬁne-tunes the distances between the two
DNA-binding domains of the PXR/RXR complex. The
lowest energy conﬁguration of the PXR/RXR complex
corresponds to the binding to DR-4, and as the bellows
of the accordion stretch out with less favorable conﬁgur-
ation, the PXR/RXR–protein complex allows the incorp-
oration of an integral number of half helical turns between
the two DNA-binding domains. As more half turns of
DNA are incorporated in the spacer region, the interface
is further stretched out, which still allows the interactions
between the PXR–protein complex and its response
element, but with decreased predilection.
Prior to this work, there were a few studies showing that
the distance between two TF binding sites can be changed
7958 Nucleic Acids Research, 2010,Vol.38, No. 22by an integral multiple of 10.5bp (the approximate
number of base pairs in one turn of the DNA helix in
solution without impairing function (38–40), but
changing the distance by a number of base pairs very dif-
ferent from multiples of 10.5bp causes severe impairment
(41). The present study also revealed that the PXR–
protein complex seems to interact with DNA with a
periodic pattern. It has provided novel aspects of the peri-
odicity of DNA related to transcriptional binding, by
demonstrating that PXR interacts with the smallest unit
of a half turn of DNA instead of a full turn. Indeed, our
ELISA-based TF-binding assays provided direct evidence
to this fact by showing that PXR indeed binds to DR-4
and DR-14 (which has one-half turn and 1.5-half turns
between the two half sites, respectively).
Contrary to reports in the literature, many motifs such
as ER-6 and ER-8, which are known PXR-response
elements in vitro (1), do not appear to be the prominent
PXR targets in vivo (Figure 8). Many well established
PXR-direct target genes as evident in vitro, including
MDR1/Mdr1 and CD36 (12,29), do not appear to have
signiﬁcant enrichment of PXR bindings in vivo.I n
addition, although the CYP4F12 gene was recently
identiﬁed as a novel PXR-direct target in cryopreserved
human hepatocytes (42), its mouse homolog Cyp4f14 is
not targeted by PXR in either control or PCN-treated
conditions in vivo liver (data not shown). Such
discrepancies in observations are likely due to the
distinct in vivo chromatin structures that mask numerous
PXR response elements by packing them into nucleo-
somes, so that only regions marked by a permissive chro-
matin signal can be accessed by the PXR protein.
Genomic regions enriched in H3K4me2 have been
shown to associate with DNase I hypersensitivity, a
marker of active-regulatory regions (43), suggesting that
the genomic regions marked with H3K4Me2 are more ac-
cessible to TFs. Furthermore, removal of H3K4Me2
prevents the recruitment of the TF FoxA1 to its
response elements (44), providing direct evidence that
H3K4Me2 predeﬁnes the binding signature of some TFs.
In contrast, minimal PXR bindings occurred at genomic
regions marked with DNAMe or H3K27Me3, suggesting
that these are non-permissive regions for PXR binding,
that likely explains why the Mdr1s, which are
PXR-direct-target genes according to in vitro evidence
(29), do not have PXR binding sites in vivo (as both of
them are marked by DNAMe).
For CD36, it has been shown that PXR binds to and
induces the mRNA expression of the CD36 gene in mouse
liver following PXR agonist administration, suggesting
that CD36 is a direct PXR-target gene (12). However, in
the present study, corresponding to the absence of a per-
missive chromatin environment, PXR binding was not
observed in the CD36 gene locus or ±10kb. The
absence of PXR binding to the CD36 gene locus is not
likely due to false negative detection, because as a positive
control, we have identiﬁed positive PXR binding
(Figure 6A) and presence of the permissive epigenetic
mark H3K4Me2 upstream of the prototypical target
gene Cyp3a11 (31), and the detection threshold was set
with sufﬁcient statistical justiﬁcation depending on the
number of tags sequenced, information on positive and
negative test sites, as well as estimation of FDR, as rec-
ommended by Genpathway (San Diego, CA). Such differ-
ences between our observations and the previous ﬁndings
(12) could be due to differences in detection methods. For
example, Zhou et al. used virus protein under the control
of the albumin promoter to over-express human PXR.
Although humanized transgenic mouse is a powerful
tool in terms of clinical signiﬁcance, the Alb-VP-hPXR
does not necessarily represent the normal amount of
mouse PXR protein under physiological conditions, and
the human PXR does not necessarily have the same
DNA-binding signatures compared to the mouse PXR.
In the previous manuscript (12), ChIP assays identiﬁed
the recruitment of mPXR onto the mCD36 promoter.
However, the PXR detected was a HA-tagged protein by
a hydrodynamic gene delivery method, and therefore does
not represent the physiological levels of mouse PXR. The
advantages of using ChIP-sequencing technology to detect
PXR DNA-binding signatures are that it provides an
unbiased genome scale information of the cistrome at
the chromatin level, instead of naked DNA (as
commonly used for gel shift assays), and reﬂects the
PXR bindings under physiological conditions, rather
than artiﬁcially over-expressed conditions.
It is interesting to note that the basolateral uptake
transporter Slco1a4 (Oatp1a4) gene has been reported to
be a direct PXR-target gene in rat liver, because PCN
signiﬁcantly enhanced the rat Oatp1a4 mRNA expression,
and electrophoretic mobility shift assays showed that PXR
binds to a DR-3 consensus sequence with the highest
afﬁnity at around 8-kb upstream of the TSS, and it
binds to two other DR-3 motifs ( 5 and  8kb, respect-
ively) with a lower afﬁnity (45). However, in mouse liver,
none of the four PXR-consensus sequences within 10-kb
upstream of the TSS of Oatp1a4, appeared to bind PXR
protein in either control or PCN-treated conditions
(Figure 1B), suggesting that PXR-DNA binding signa-
tures are species speciﬁc. Interestingly, unbiased
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Nucleic Acids Research, 2010,Vol.38, No. 22 7959ChIP-sequencing has identiﬁed one site at 10-kb upstream
of the TSS of Oatp1a4 with strong enrichment of PXR
binding in control liver, which further increased after
PCN treatment (Supplementary Figure S9). Although
there were no known PXR-consensus sequences (DR-3,
DR-4, ER-6 and ER-8) observed in this region using con-
ventional methods, which have limited settings for the
spacer distance (NHR-scan and NUBI-scan, data not
shown), our novel motif detection algorithm has identiﬁed
one DR-9-like consensus sequence present in the
PXR-binding site for Oatp1a4, which is shown for the
ﬁrst time in the present study to be a PXR
DNA-binding motif (DR-(5n+4) periodic pattern,
n=1). TF-binding assays validated that PXR protein
indeed binds to the DR-9 sequence (Figure 9), and
PXR-dependent mRNA induction of Oatp1a4 was
observed in mouse liver (Table 2). Taken together, our
results from ChIP-sequencing, motif analysis,
TF-binding assays, as well as mRNA assays in WT and
PXR-null mice have lead to the conclusion that Oatp1a4 is
a direct PXR-target gene in mouse liver, with a novel PXR
DNA-binding signature in vivo.
The current study has revealed both PXR-induced and
suppressed direct-target gene batteries, raising the
question of how the same TF exerts different gene regu-
latory functions. Previous studies have shown that the
C-terminal helix of PXR (termed AF-2) is responsible
for recruiting either co-activators, like the steroid
receptor co-activator 1 (SRC1), or co-repressors, like the
nuclear receptor co-repressor 2 (NCoR2/SMRT) (42,46).
In addition, PXR can interact with other TFs and alter
their target-gene expression (47). This shows the
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Figure 9. Quantiﬁcation of PXR binding to the DR-3, DR-4, DR-9, DR-14 and DR-19 DNA-binding motifs. Nuclear protein extracts from the
livers of mice treated with corn oil vehicle control (CON) or the PXR agonist, PCN, were incubated with oligonucleotides corresponding to various
DNA-binding motifs. The binding of PXR to the various DNA-binding motifs was quantiﬁed using an ELISA-based TF binding assay, as detailed in
the Methods section. Binding of PXR to (A) DR-3, (B) DR-4, (C) DR-9, (D) DR-14 and (E) DR-19. An unlabeled oligonucleotide competitor was
included for each DR DNA-binding motif to conﬁrm the speciﬁcity of the assay (WT Comp) as well as a mutated oligonucleotide competitor which
should not compete effectively with the positive control (PCN treatment). (F) PXR binding to all the DNA-binding motifs was analyzed simultan-
eously in order to directly compare the intensity of binding among the different DR sequences.
7960 Nucleic Acids Research, 2010,Vol.38, No. 22complexity of the role of PXR in regulating gene expres-
sion in vivo, where numerous other transcription regula-
tors are present.
Unbiased ChIP-Seq analysis has identiﬁed numerous
PXR-binding sites within introns and downstream of the
target gene loci, in addition to binding sites found in pro-
moters (Figure 6 and Supplementary Figures S3–S5),
which are in agreement with genome-wide ChIP-based
studies for PXR binding, using cryopreserved human hep-
atocytes (42). Numerous studies in the literature have
shown that regulatory elements in introns, exons and
further downstream are critical in regulating transcription
(48–51). Therefore, it appears that PXR-binding sites are
likely important wherever they are positioned around the
gene loci, and do not necessarily need to be located in the
50 ﬂanking regions. It has been shown that widely spaced
genomic response elements (e.g. in promoters and termin-
ators) can communicate in the third dimension by forming
‘chromatin loops’, which facilitates the re-initiation of
transcription (52). It is possible that PXR might use the
same strategy to enhance the transcription efﬁciency of
target genes by drifting among multiple binding sites
within a gene locus.
It is generally considered that PXR is a key regulator of
drug metabolism and transport in liver. Therefore, it is
critical to understand how PXR is recruited to the
response elements of the target genes encoding
drug-metabolizing enzymes and transporters. As a ﬁrst
attempt to discover the roles of epigenetic signatures in
regulating PXR bindings to drug-processing genes, we
selected chromosomes 5, 12 and 15, because these chromo-
somes are enriched with drug-processing genes. For
example, for Phase I drug metabolism, the entire Cyp3a
family members are transcribed from chromosome 5, and
it is well known that cytochrome P450 3A enzymes are
major drug-metabolizing enzymes, responsible for
metabolizing >50% of prescribed drugs and some en-
dogenous compounds (53). For Phase II drug metabolism,
the entire Ugt2 and Ugt3 gene clusters are localized to
chromosome 5 and 15, respectively. Ugts encode
UDP-glucuronosyltransferases that conjugate lipophilic
substrates with glucuronic acid, thereby increasing hydro-
philicity and enhancing excretion through bile and urine,
serving as one of the major mechanisms for detoxiﬁcation
of chemicals. For transporters, the entire Mdr gene cluster
(Mdr1a, 1b and 2), which encodes critical
multidrug-resistance transporters for the excretion of
drugs (Mdr1a and 1b) and phospolipids (Mdr2), are
localized on chromosome 5. In addition, these chromo-
somes contain genes encoding several critical TFs and
cofactors for xenobiotic metabolism and disposition,
including the aryl hydrocarbon receptor (Ahr) on chromo-
some 12, peroxisome proliferator activated receptor alpha
(PPARa) on chromosome 15, and peroxisome prolifera-
tive activated receptor, gamma, coactivator 1 alpha
(PGC-1a) on chromosome 5. Therefore, these three
chromosomes were selected to determine the roles of epi-
genetic signatures in PXR–DNA bindings and the target
gene expression. The roles of various epigenetic marks,
including DNA and histone methylation and various
other histone modiﬁcations (acetylation, phosphorylation,
etc.) in PXR–DNA binding in the entire genome will be
examined in future studies.
PXR-mediated gene regulation is apparently tissue and
gender speciﬁc. For example, the PXR agonist PCN
induces Mdr1a, 1b and Mdr2 gene expression in mouse
brain, induces Mdr1a in intestine, but induces none of the
Mdrs in liver (33). For Gsts, it has been shown by Gong
et al. that PXR regulates glutathione S-transferase expres-
sion in an isozyme-, tissue- and gender-speciﬁc manner
(54). It still remains a mystery how PXR-target genes
are regulated in tissue and gender speciﬁc manner.
Accumulating evidence in the literature suggests that the
tissue speciﬁcity of drug-processing gene expression may
be due to distinct epigenetic mechanisms. For example, it
has been shown by Dr Sugiyama’s group that epigenetic
regulation underlies the tissue-speciﬁc expression of mouse
liver-speciﬁc transporters (55). They examined the DNA
methylation and histone modiﬁcation proﬁles near the
TSS of various transporters in liver, kidney and
cerebrum. Genome-wide DNA methylation proﬁling
demonstrated that the CpG dinucleotides around the
TSS of liver-enriched transporters were hypomethylated
in liver, but hypermethylated in kidney and cerebrum
where these transporters are expressed lowly, whereas
the opposite pattern was observed for kidney and
cerebrum-enriched transporters; whereas the histone H3
associated with liver-enriched transporter gene promoters
was hyperacetylated in the liver but was acetylated very
little in kidney and cerebrum, and the opposite pattern
holds true for kidney and cerebrum-enriched genes.
These results suggest the epigenetic mechanisms are
critical in determining the tissue speciﬁcity of genes. In
addition, tissue-speciﬁc cofactors may contribute to
tissue speciﬁcity of gene expression. For example, very
recently, the DNA-binding signatures of FXR in mouse
liver and ileum have been characterized using ChIP-Seq,
and a large degree of tissue-speciﬁc FXR binding has been
identiﬁed, with only 11% of total sites shared between
liver and intestine. Motif analysis revealed a half nuclear
receptor binding site, normally bound by a few orphan
nuclear receptors, adjacent to the FXR-response
elements, indicating possible involvement of some
orphan nuclear receptors in modulating FXR function
(56). In summary, the tissue speciﬁcity of nuclear-
receptor-mediated gene expression may be determined by
epigenetic mechanisms and tissue-speciﬁc cofactors.
Presence of PXR–DNA bindings, co-existence of various
DNA and histone epigenetic marks, as well as the inter-
actions between PXR and critical cofactors, will be
determined by ChIP-Seq in future studies.
In conclusion, the current work offers new insights in
understanding the nuclear binding signatures, direct
targets and potential epigenetic cofactors of the hepatic
nuclear receptor PXR in vivo, paving the path for
further understanding the multifaceted roles of hepatic
PXR in mediating the physiological and pharmacological
responses in humans. In spite of extensive research in the
area, we are still learning the true nature of the nuclear
receptor–DNA interactions that play a key part of gene
regulation during physiological and pharmacological re-
sponses. By looking beyond the generally expected short
Nucleic Acids Research, 2010,Vol.38, No. 22 7961nuclear receptor binding motif (no more than eight
spacers as reported in the literature) using a novel compu-
tational method, we were able to identify not only very
long regulatory elements, but also an underlying periodic
pattern in the spacer distance. In addition, with the advent
of next generation DNA sequencing and other
genomic-scale technologies, it is now possible to obtain
genome-scale in vivo protein–DNA interaction data,
which not only allows us to determine the DNA-binding
signatures of a particular nuclear receptor, but also its
interactions between co-localizing regulatory factors,
including epigenetic marks. By combining the
genome-wide location analysis of the nuclear receptor
PXR, extensive computational analysis on its
DNA-binding motifs, its co-localization with epigenetic
signatures, microarray proﬁling of PXR-target gene ex-
pression and pathway analysis, and validation in
PXR-null mice, the present study has set an example of
exploring novel functions of nuclear receptors in vivo.
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